{"summary": "Author is long CRDF as a micro-cap biotech with a Phase 3 catalyst, a large insider purchase, and an NMS patent lawsuit that could resolve favorably.", "reason": "The author provides a detailed investment thesis based on clinical catalysts and legal developments.", "ideas": [{"symbol": "CRDF", "direction": "long", "thesis": "The author is bullish on Cardiff Oncology (CRDF) because onvansertib targets first-line RAS-mutated metastatic colorectal cancer, a large underserved market, with recent readouts suggesting it beats standard-of-care and a Phase 3 targeted for Q1 2027 after a successful End of Phase 2 FDA meeting. The author was drawn in by Gary Pace's roughly $1M insider purchase at a cost average near $1.50, above the current price, and expects progress in Cardiff's California lawsuit against NMS over patent inventorship to lift shares. The author believes NMS is using the joint inventorship claim as a negotiation tactic to reprice the 2017 license, and views court progress as a near-term catalyst. The main risk is the legal dispute itself, including NMS's attempt to terminate the agreement and the possibility of an unfavorable ruling.", "thesis_short": "Long CRDF on Ph3 catalyst and NMS lawsuit progress", "quote": "I got into this after seeing a very large $1M insider purchase (Gary Pace) recently. His cost average is roughly a buck and half-ish - we haven't even hit that yet. Today, on a red day for most penny stocks this one is up. All it needs is progress in court which could hit any day now - and I believe it's onward and upward from there.", "confidence": 0.8, "sentiment": 0.75, "timeframe": "near-term court progress; Phase 3 targeted Q1 2027"}], "model": "gemini-3.1-flash-lite", "verified": true, "extraction_model": "deepseek-v4-flash"}
This Reddit post, published September 10, 2026, features u/SeniorVicePrez discussing CRDF. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/SeniorVicePrez · Tickers: CRDF